Suppr超能文献

甲状腺癌术后低活性(2.0 GBq;54 mCi)放射性碘残余甲状腺组织消融:低风险患者中激素撤停与重组人促甲状腺素使用的比较。

Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients.

作者信息

Chianelli M, Todino V, Graziano F M, Panunzi C, Pace D, Guglielmi R, Signore A, Papini E

机构信息

Nuclear Medicine Unit, Department of Diagnostics, Regina Apostolorum Hospital, Albano, Rome, Italy.

出版信息

Eur J Endocrinol. 2009 Mar;160(3):431-6. doi: 10.1530/EJE-08-0669. Epub 2008 Dec 12.

Abstract

OBJECTIVE

(a) To compare the efficacy of low-activity (2 GBq; 54 mCi) (131)I ablation using l-thyroxine withdrawal or rhTSH stimulation, and (b) to assess the influence of thyroid remnants volume on the ablation rate.

DESIGN

Patients underwent neck ultrasound, (131)I neck scintigraphy and radioiodine uptake. Post-therapy whole body scan (WBS) was acquired after 4-6 days. Ablation was assessed after 6-12 months by WBS, Tg and TgAb following l-thyroxine withdrawal.

METHODS

Group A: preparation by L-T(4) withdrawal (37 days); 21 patients received (131)I (2.02+/-0.22 GBq; 54.6+/-5.9 mCi) and on the day of treatment, TSH, Tg, TgAb were measured; Group B: stimulation by rhTSH; 21 patients received (131)I (1.97+/-0.18 GBq; 53.2+/-4.9 mCi) 24 h after the second injection of rhTSH (0.9 mg) and TSH, Tg and TgAb were measured after 2 days.

RESULTS

At follow-up, 90.0% of patients from group A and 85.0% of patients from group B had Tg levels <1 ng/ml; no uptake was observed in 95.2% and in 90.5% of patients from group A or B respectively, with no statistical differences for both ablation criteria. Before (131)I treatment, small thyroid remnants (<1 ml) were detected by US in <25% of all patients.

CONCLUSIONS

The use of rhTSH for the preparation of low-risk patients to ablation therapy with low activities of (131)I (2 GBq; 54 mCi) is safe and effective and avoids hypothyroidism. The presence of thyroid remnants smaller than 1 ml at US evaluation had no effect on the ablation rate.

摘要

目的

(a) 比较采用左旋甲状腺素撤药或重组人促甲状腺素(rhTSH)刺激进行低活度(2GBq;54mCi)(131)I消融的疗效,以及(b) 评估甲状腺残余体积对消融率的影响。

设计

患者接受颈部超声、(131)I颈部闪烁扫描及放射性碘摄取检查。治疗后4 - 6天进行治疗后全身扫描(WBS)。在左旋甲状腺素撤药后6 - 12个月,通过WBS、Tg和TgAb评估消融情况。

方法

A组:通过左旋甲状腺素撤药进行准备(37天);21例患者接受(131)I(2.02±0.22GBq;54.6±5.9mCi),并在治疗当天测量TSH、Tg、TgAb;B组:通过rhTSH刺激;21例患者在第二次注射rhTSH(0.9mg)24小时后接受(131)I(1.97±0.18GBq;53.2±4.9mCi),并在2天后测量TSH、Tg和TgAb。

结果

随访时,A组90.0%的患者和B组85.0%的患者Tg水平<1ng/ml;A组和B组分别有95.2%和90.5%的患者未观察到摄取,两种消融标准均无统计学差异。在(131)I治疗前,超声检查发现<25%的所有患者存在小的甲状腺残余(<1ml)。

结论

对于低风险患者,使用rhTSH准备低活度(2GBq;54mCi)(131)I消融治疗是安全有效的,且可避免甲状腺功能减退。超声评估时甲状腺残余小于1ml对消融率无影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验